Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) announced it will regain full rights to its in vivo chronic hepatitis B virus (HBV) program previously developed in collaboration with Gilead Sciences. The company valued the collaboration, which is set to conclude on September 4, 2020, and anticipates no changes to its cash runway. As of March 31, 2020, cash and cash equivalents stood at $154.2 million, expected to fund operations into mid-2021. ARCUS gene editing has shown promise in targeting HBV, with preclinical data demonstrating significant effectiveness in knocking down HBV genomes.
Precision BioSciences (Nasdaq: DTIL) has initiated a Phase 1/2a clinical trial for its third allogeneic CAR T therapy candidate, PBCAR269A, targeting relapsed/refractory multiple myeloma. The first patient has been dosed, with the trial emphasizing the use of clinical materials produced at the company's in-house facility. PBCAR269A has shown promise in preclinical models, effectively reducing BCMA+ tumor cells without causing graft-versus-host disease. The FDA has granted it Orphan Drug Designation for multiple myeloma treatment.
Precision BioSciences (DTIL), a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 3, 2020, where CEO Matt Kane will speak from 9:30 AM to 9:55 AM ET. Following that, the company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, with Kane speaking from 8:50 AM to 9:30 AM ET. Live webcasts can be accessed on the company’s website, with replays available for 30 days post-presentation.
Summary not available.